National Eye Institute Gene Therapy Delivery Device Trial Evaluated
This article was originally published in The Gray Sheet
Executive Summary
Direct retinal delivery of recombinant proteins in patients with the heterogeneous genetic disease retinitis pigmentosa (RP) is the first eye therapy endorsed for evaluation by the Recombinant DNA Advisory Committee